Aimmune Therapeutics Inc (NASDAQ:AIMT) insider Jayson Donald Alexander Dallas purchased 3,650 shares of Aimmune Therapeutics stock in a transaction on Monday, November 19th. The shares were acquired at an average cost of $27.56 per share, for a total transaction of $100,594.00. Following the completion of the transaction, the insider now owns 63,600 shares of the company’s stock, valued at $1,752,816. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of AIMT traded down $3.33 during mid-day trading on Monday, reaching $26.29. 2,427,529 shares of the stock traded hands, compared to its average volume of 644,739. The firm has a market capitalization of $1.74 billion, a P/E ratio of -10.07 and a beta of -0.10. Aimmune Therapeutics Inc has a 12-month low of $24.56 and a 12-month high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.03. As a group, analysts forecast that Aimmune Therapeutics Inc will post -3.65 earnings per share for the current year.

AIMT has been the topic of a number of recent research reports. BidaskClub cut shares of Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 11th. Roth Capital set a $80.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 9th. Wedbush initiated coverage on shares of Aimmune Therapeutics in a research report on Wednesday, October 17th. They set a “buy” rating and a $72.00 price target on the stock. ValuEngine raised shares of Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 17th. Finally, Stifel Nicolaus initiated coverage on shares of Aimmune Therapeutics in a research report on Thursday, September 13th. They set a “hold” rating and a $33.00 price target on the stock. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Aimmune Therapeutics has an average rating of “Buy” and a consensus target price of $51.50.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Teachers Advisors LLC raised its stake in shares of Aimmune Therapeutics by 25.2% during the third quarter. Teachers Advisors LLC now owns 103,078 shares of the biotechnology company’s stock valued at $2,812,000 after purchasing an additional 20,751 shares during the period. MetLife Investment Advisors LLC raised its stake in shares of Aimmune Therapeutics by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 31,568 shares of the biotechnology company’s stock valued at $861,000 after purchasing an additional 11,222 shares during the period. Man Group plc raised its stake in shares of Aimmune Therapeutics by 199.0% during the third quarter. Man Group plc now owns 16,550 shares of the biotechnology company’s stock valued at $451,000 after purchasing an additional 11,014 shares during the period. Paloma Partners Management Co purchased a new stake in shares of Aimmune Therapeutics during the third quarter valued at approximately $323,000. Finally, Jane Street Group LLC raised its stake in shares of Aimmune Therapeutics by 141.4% during the third quarter. Jane Street Group LLC now owns 19,072 shares of the biotechnology company’s stock valued at $520,000 after purchasing an additional 11,172 shares during the period. Institutional investors own 76.92% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Jayson Donald Alexander Dallas Purchases 3,650 Shares of Aimmune Therapeutics Inc (AIMT) Stock” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/19/jayson-donald-alexander-dallas-purchases-3650-shares-of-aimmune-therapeutics-inc-aimt-stock.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Further Reading: Tariff

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.